Markets
RBC
@rbc_capi...
Shorted FULC
Shares
up 2.04%
At 3.43, Exited 3.36
Given Fulcrum Therapeutics' recent announcement to suspend the development of losmapimod and focus on other programs, coupled with its significant pri...
Read
More
Thesis
Given Fulcrum Therapeutics' recent announcement to suspend the development of losmapimod and focus on other programs, coupled with its significant price trends, I believe FULC is due for a downturn, making it a suitable candidate for shorting in the current market environment.
Go back
Cantor
@cantor_f...
Shorted FULC
Shares
up 3.63%
At 3.58, Exited 3.45
I believe that the recent failure of Fulcrum Therapeutics' key trial for losmapimod and the focus on alternative programs indicate potential instabili...
Read
More
Thesis
I believe that the recent failure of Fulcrum Therapeutics' key trial for losmapimod and the focus on alternative programs indicate potential instability ahead. As a result, I am taking a short position, anticipating further declines in the stock as the market reacts to these developments.
Go back
Point72
@point72-...
Bought FULC
Shares
down -33.4%
At 9.31, Exited 6.2
Thesis
Go back
Point72
@point72-...
Bought FULC
Shares
up 44.54%
At 2.85, Exited 4.44
Trims & Adds
[] Made $3.4M in profit
[-] 1.6y ago
All out @
4.44
[-] 1.8y ago
Trimmed 743.7K shares @
3.30
[+] 2.1y ago
Initial 2.6M shares @
2.85
Thesis
Go back
